Grant Award Details

Battling COVID-19 Using Off-The-Shelf HSC-Engineered iNKT Cells
Grant Number: 
DISC2COVID19-12020
Project Objective: 
  • The objective of this award is to develop an allogeneic HSC-engineered iNKT (HSC-iNKT) cell therapy for treating COVID-19 patients.
Investigator: 
Name: 
Type: 
PI
Disease Focus: 
COVID-19
Infectious Disease
Human Stem Cell Use: 
Adult Stem Cell
Award Value: 
$250,000
Status: 
Active

Grant Application Details

Application Title: 
  • Battling COVID-19 Using Off-The-Shelf HSC-Engineered iNKT Cells
Public Abstract: 

Research Objective

allogeneic HSC-engineered iNKT (HSC-iNKT) cells

Impact

treatment for COVID-19

Major Proposed Activities

  • Milestone 1. Production of AlloHSC-iNKT and UHSC-iNKT cells
  • Milestone 2. Characterization of the AlloHSC-iNKT and UHSC-iNKT cells
  • Milestone 3. Delivery of the new therapeutic candidate
Statement of Benefit to California: 

The novel SARS-CoV-2 is the cause of the coronavirus disease 19 (COVID-19) pandemic, which is responsible for over 10.3 million cases and 500,000 deaths worldwide. There are over 2.6 million COVID-19 cases in the US, including over 217,000 cases in California. The proposed off-the-shelf allogeneic HSC-engineered iNKT (HSC-iNKT) cell therapy, if successful, may provide a treatment and save lives of COVID-19 patients at California.